Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
Pevonedistat 25 mg/m^2
Takeda
Leukemia, Myeloid, Acute
1 trial -
Ph 1 Study of ORIC-944 in Patients with Metastatic Prostate Cancer.
Topiloric/Uriadec
Prostate cancer
1 trial -
Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers
Immunocore Ireland Limited
Advanced PRAME Positive Cancers
1 trial -
Phase 1 Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancer
Janssen-Cilag International N.V.
Metastatic colorectal cancer and Gastric cancer
1 trial -
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Olema Pharmaceuticals
Advanced or Metastatic Solid Tumors
1 trial -
Phase 1 Study of PYX-106 in Solid Tumors
Pyxis Oncology
Solid Tumors
1 trial -
Phase 1 Study of PYX-201 in Solid Tumors
Pyxis Oncology
Advanced solid tumors
1 trial -
Phase 1 trial of valemetostat and darolutamide in mCRPC
Daiichi Sankyo
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1 trial -
Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer
Amgen
Small Cell Lung Cancer
1 trial -
Phase I Study of PM54 Administered to Patients with Advanced Solid Tumors
Lacuna Pharma Pty Ltd
Selected Advanced Solid Tumors
1 trial -
Phase I study of 225Ac-PSMA I&T in prostate cancer
Disc Medicine
metastatic prostate cancer
1 trial -
Phase I study of MGY825 in patients with lung cancer
Novartis Pharmaceuticals
Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients
1 trial -
Pitavastatin
United Therapeutics Europe Ltd
Acute Myeloid Leukemia
1 trial -
Placebo for antibiotic
Seres Therapeutics
Metastatic Melanoma
1 trial -
Plerixafor
United Therapeutics Europe Ltd
Pancreatic Adenocarcinoma Metastatic
1 trial -
Ponatinib
Takeda
Chronic Myelogenous Leukemia
1 trial -
Prizloncabtagene Autoleucel
The First People's Hospital of Lianyungang
Non-Hodgkin's B-cell Lymphoma
1 trial -
Proxalutamide
The First People's Hospital of Lianyungang
Metastatic Breast Cancer
1 trial -
Pyrotinib low dose group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
QEQ278
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
1 trial -
R1979-HM-1333
Lacuna Pharma Pty Ltd
B-cell non-Hodgkin lymphoma (NHL)
1 trial -
R1979-ONC-1504
Lacuna Pharma Pty Ltd
B-Cell Non-Hodgkin’s Lymphoma (B-NHL)
1 trial -
R2810-ONC-1787
Lacuna Pharma Pty Ltd
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
1 trial -
R4-FOUR-PET
Fondazione Telethon ETS
Advanced solid neoplasm (breast, lung, colon, ovary, pancreas) characterized by positive CXCR4 expression by immunohistochemistry
1 trial -
R5054-ONC-1843
Lacuna Pharma Pty Ltd
Advanced Solid Tumor
1 trial -
R6569-ONC-1933
Lacuna Pharma Pty Ltd
Squamous Cell Carcinoma of Head and Neck
1 trial -
RAD 001 in combination with Caelyx
BRIGHT MINDS BIOSCIENCES INC.
Advanced Solid Tumors
1 trial -
RBL001/RBL002
Atrium Therapeutics
Melanoma
1 trial -
REGN1400
Regeneron UK Limited
Cancer
1 trial -
REGN2810
Regeneron UK Limited
Melanoma
1 trial -
REGN2810
Regeneron UK Limited
Recurrent Squamous Cell Carcinoma of Head
1 trial -
REGN4659
Regeneron UK Limited
Carcinoma, Non-Small-Cell Lung
1 trial -
REGN5678
Regeneron UK Limited
Prostate Cancer
1 trial -
REGN6569
Regeneron UK Limited
Squamous Cell Carcinoma of Head and Neck
1 trial -
REOLYSIN®
ONCOLYTICS BIOTECH INC
Muscle-invasive Transitional Cell Carcinoma of the Bladder
1 trial -
REOLYSIN®
ONCOLYTICS BIOTECH INC
KRAS Mutant Metastatic Colorectal Cancer
1 trial -
REOLYSIN®
ONCOLYTICS BIOTECH INC
Pancreatic Adenocarcinoma
1 trial -
RESTART; Autologous Transplantation of Adult...
Disc Medicine
Patients operated with curative intend for head and neck cancer with an indication for bilateral postoperative radiotherapy, with or without chemotherapy.
1 trial -
RJMty19 (CD19-CAR-DNT cells)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
B-cell Non-Hodgkin's Lymphoma
1 trial -
RMC-4630
Revolution Medicines
Solid Tumors
1 trial -
RMC-5127
Revolution Medicines
Non-small Cell Lung Cancer (NSCLC)
1 trial -
RMC-5552
Revolution Medicines
Solid Tumors
1 trial -
RMC-6291
Revolution Medicines
Non-Small Cell Lung Cancer (NSCLC)
2 trials -
RMC-6291-001
Revolution Medicines
Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor, Colorectal Cancer (CRC)
1 trial -
RMC-6291-101
Revolution Medicines
Participants with Advanced KRASG12C-Mutated Solid Tumors
1 trial -
RMC-9805
Revolution Medicines
Non-small Cell Lung Cancer (NSCLC)
1 trial -
RMC-LUNG-101A
Revolution Medicines
Lung Cancer
1 trial -
RMC-LUNG-101B
Revolution Medicines
Lung Cancer
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.